NASDAQ$OFIX
Orthofix Medical Inc · Q4 2020 earnings
Q4 2020 earnings · · Investor relations
Briefing
Reported results for the fourth quarter and fiscal year 2020.
Orthofix reported Q4 net sales of $117.6 million, EPS of $(0.48), and adjusted EPS of $0.44. The company drove revenue close to 2019 levels while solidifying its organization amidst global elective procedure restrictions. They are shifting their transformation to execution phase, aiming for growth and high-value solutions.
- Fourth quarter net sales of $117.6 million, within 3% of 2019 results.
- US Spine implant sales grew 11% compared to fourth quarter 2019, driven by record M6-C artificial cervical disc performance.
- Strong cash flow performance in the quarter, free cash flow of $17.9 million.
- FITBONE® intramedullary lengthening and deformity system receives FDA clearance for pediatric indication.
Headline financials
Revenue & EPS history
Orthofix · Revenue · Quarterly
$118M
Revenue by segment
Orthofix · $78.3M total across 2 segments · Q4 2020
- Bone Growth Therapies$50.5M-0.9%64.5%
- Spinal Implants & Biologics$27.8M+9.3%35.5%
Forward guidance
Orthofix expects net sales between $445.0 and $460.0 million for the full year 2021. For Q1 2021, they anticipate net sales between $95.0 and $96.0 million, adjusted EBITDA between $50.0 and $54.0 million, and adjusted EPS between $0.45 and $0.55.
Tailwinds
- Year-over-year increase of 9.5% to 13.1% on a reported basis for full year net sales.
- Expected rebounds in procedural volumes and case complexity in the third and fourth quarters.
- Q1 2021 adjusted EBITDA represents a year-over-year increase of 5.0% to 13.4%.
- Q1 2021 adjusted EPS represents a year-over-year increase of 73.1% to 111.5%.
- Expect improvements in March in procedural volume declines.
Headwinds
- COVID-19 restrictions have increased over December 2020 measures.
- Procedural volume declines of approximately 15% from January through early February.
- Weather emergency experienced last week will likely have an additional negative impact on our business for the first quarter.
- Anticipate a modest impact from COVID-19 related restrictions into the second quarter.
- Q1 2021 net sales represents a year-over-year decrease of 9.4% to 8.4% on a reported basis
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q4 2020
-0.9%
Avg return
Earnings day
-2.6%
Avg return
5 days after
-3.4%
Avg return
30 days after
48%
31 / 65 earnings
Positive
+20.3%
Q2 2014
Best reaction
-18.5%
Q4 2019
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +3.8% | -2.8% | -13.8% | |
| Q4 2025 | -7.0% | -0.4% | -13.2% | |
| Q3 2025 | -7.4% | -6.8% | -1.0% | |
| Q1 2025 | -10.8% | -10.6% | -20.9% | |
| Q4 2024 | -3.5% | -4.2% | -11.0% | |
| Q3 2024 | +5.5% | +4.6% | +1.2% | |
| Q2 2024 | +13.8% | +10.8% | +16.7% | |
| Q1 2024 | +10.7% | +8.8% | +0.6% | |
| Q4 2023 | +8.1% | +7.1% | +8.6% | |
| Q3 2023 | -12.5% | -20.2% | -3.2% | |
| Q2 2023 | +9.9% | +7.6% | +1.3% | |
| Q1 2023 | +1.0% | -2.3% | +6.7% | |
| Q4 2022 | -7.7% | -13.2% | -15.5% | |
| Q3 2022 | -2.2% | +4.1% | +30.5% | |
| Q2 2022 | -6.6% | -8.8% | -20.9% | |
| Q1 2022 | -10.5% | -14.3% | -11.6% | |
| Q4 2021 | +4.0% | +3.5% | +0.4% | |
| Q3 2021 | -5.9% | -10.9% | -18.6% | |
| Q2 2021 | +8.9% | +4.1% | +12.4% | |
| Q1 2021 | +0.5% | -2.0% | -8.7% | |
| Q4 2020 | +0.6% | -0.5% | -7.3% | |
| Q3 2020 | +5.2% | +13.6% | +10.8% | |
| Q2 2020 | +4.5% | +4.6% | -13.4% | |
| Q1 2020 | -1.9% | -6.9% | +3.9% | |
| Q4 2019 | -18.5% | -21.5% | -40.9% | |
| Q3 2019 | -16.8% | -17.0% | -9.6% | |
| Q2 2019 | +0.1% | +2.6% | -5.5% | |
| Q1 2019 | -2.6% | -0.3% | -10.9% | |
| Q4 2018 | -8.5% | -10.0% | -14.8% | |
| Q3 2018 | +7.4% | +8.8% | +4.1% | |
| Q2 2018 | -15.1% | -11.9% | -12.1% | |
| Q1 2018 | -13.4% | -14.6% | -10.5% | |
| Q4 2017 | +6.4% | +4.6% | +8.4% | |
| Q3 2017 | +8.8% | +5.1% | +9.6% | |
| Q2 2017 | +9.9% | +6.8% | +12.3% | |
| Q1 2017 | +1.4% | +3.8% | +8.2% | |
| Q4 2016 | -6.1% | -4.8% | +2.6% | |
| Q3 2016 | -3.8% | -6.8% | -1.5% | |
| Q2 2016 | -10.4% | -10.5% | -4.8% | |
| Q1 2016 | +0.4% | — | — | |
| Q4 2015 | +2.8% | — | — | |
| Q3 2015 | +14.4% | — | — | |
| Q2 2015 | +13.8% | — | — | |
| Q1 2015 | +0.4% | — | — | |
| Q4 2014 | -10.8% | — | — | |
| Q3 2014 | +20.3% | — | — | |
| Q2 2014 | +20.3% | — | — | |
| Q1 2014 | +4.2% | — | — | |
| Q4 2013 | +14.1% | — | — | |
| Q3 2013 | +1.1% | — | — | |
| Q2 2013 | -0.8% | — | — | |
| Q1 2013 | -16.4% | — | — | |
| Q4 2012 | -4.9% | — | — | |
| Q3 2012 | -2.8% | — | — | |
| Q2 2012 | +4.5% | — | — | |
| Q1 2011 | -0.7% | — | — | |
| Q1 2012 | +1.0% | — | — | |
| Q1 2010 | -4.8% | — | — | |
| Q4 2011 | -4.8% | — | — | |
| Q4 2009 | -4.8% | — | — | |
| Q3 2010 | -7.4% | — | — | |
| Q3 2011 | -7.4% | — | — | |
| Q4 2010 | -9.5% | — | — | |
| Q2 2010 | -9.5% | — | — | |
| Q2 2011 | -9.5% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro